Company intelligence / Profile preview
Brenig Therapeutics
Dover, Delaware, United Statesbrenigther.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BT-267, their lead LRRK2 inhibitor, has entered Phase 1 clinical trials as of November 2024. Preclinical data showed superior safety profile with exceptional CSF to plasma ratio, in vivo efficacy in brain, and no visible lung and kidney morphological changes compared to other LRRK2 inhibitor candidates.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Expert Systems Inc. (drug accelerator)
Beyond the preview
Go deeper on Brenig Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brenig Therapeutics.